Botanix Pharmaceuticals Limited
ASX: BOT
Commercial launch gaining traction as capitulation pricing opens recovery potential.
(Source: TradingView) 3-Month Performance Profile of BOT on a DTF compared to S&P/ASX 200 (XJO).
Botanix Pharmaceuticals reported a transformational first-half FY26 result, driven by the successful launch of Sofdra. Reported revenue rose sharply to $16.5 m
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
